25083-80-1

Usage

Uses

Used in Pharmaceutical Industry:
6-(benzyloxy)-2,3-dihydroinden-1-one is used as a building block for the synthesis of various drugs, contributing to the development of new therapeutic agents. Its unique chemical properties allow it to be a key component in the formulation of pharmaceuticals, enhancing their efficacy and potential applications in treating various health conditions.
Used in Organic Chemistry:
In the realm of organic chemistry, 6-(benzyloxy)-2,3-dihydroinden-1-one serves as a versatile reagent, facilitating the synthesis of complex organic molecules. Its reactivity and structural features make it an essential tool for researchers and chemists in advancing the field of organic chemistry.
Used in Material Science:
6-(benzyloxy)-2,3-dihydroinden-1-one is also recognized for its potential use in the development of new materials. Its unique properties and reactivity contribute to the creation of innovative materials with specific characteristics, such as improved strength, stability, or other desirable attributes.
Used in Chemical Research:
As a reagent in chemical research, 6-(benzyloxy)-2,3-dihydroinden-1-one plays a crucial role in advancing scientific knowledge and understanding of chemical reactions and processes. Its unique structure and reactivity make it an indispensable component in various experimental setups, aiding researchers in exploring new chemical pathways and mechanisms.

Upstream product

• 62803-47-8 6-hydroxy-1-indanone 
• 100-39-0 benzyl bromide 
• 1972-28-7 diethylazodicarboxylate 

Downstream Products

• 1022980-12-6 3-allyl-6-(benzyloxy)indan-1-one 
• 1195221-84-1 6-(benzyloxy)-2,3-dihydro-1H-inden-1-ol 
• 1446091-32-2 5-(benzyloxy)-1H-indene 
• 1435275-70-9 C₁₇H₁₆O 
• 1222092-17-2 C₃₅H₃₇FO₄ 
• 1435275-76-5 (1R,2R)-ethyl 6'-(benzyloxy)-2',3'-dihydrospiro[cyclopropane-1,1'-indene]-2-carboxylate 
• 1187197-98-3 C₃₃H₃₅FO₄ 
• 1448668-63-0 C₃₅H₃₉FO₄ 
• 1222088-92-7 (1R,2R)-6'-((2-((S)-2,2-dimethylcyclopentyl)-2'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methoxy)-2',3'-dihydrospiro[cyclopropane-1,1'-indene]-2-carboxylic acid 
• 1222088-90-5 AM-5262 
• 1222088-82-5 (1R,2R)-6'-((2-(5,5-dimethylcyclopent-1-en-1-yl)-2'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methoxy)-2',3'-dihydrospiro[cyclopropane-1,1'-indene]-2-carboxylic acid 
• 1187198-00-0 (R)-2-(6-((2-(5,5-dimethylcyclopent-1-en-1-yl)-2'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methoxy)-2,3-dihydro-1H-inden-1-yl)acetic acid 

Relevant academic research and scientific papers

Indanones as high-potency reversible inhibitors of monoamine oxidase

Recent reports document that α-tetralone (3,4-dihydro-2H-naphthalen-1-one) is an appropriate scaffold for the design of high-potency monoamine oxidase (MAO) inhibitors. Based on the structural similarity between α-tetralone and 1-indanone, the present stu

Adenosine A2AR/A1R Antagonists Enabling Additional H3R Antagonism for the Treatment of Parkinson’s Disease

Adenosine A1/A2Areceptors (A1R/A2AR) represent targets in nondopaminergic treatment of motor disorders such as Parkinson’s disease (PD). As an innovative strategy, multitargeting ligands (MTLs) were developed to achieve comprehensive PD therapies simultaneously addressing comorbid symptoms such as sleep disruption. Recognizing the wake-promoting capacity of histamine H3receptor (H3R) antagonists in combination with the “caffeine-like effects” of A1R/A2AR antagonists, we designed A1R/A2AR/H3R MTLs, where a piperidino-/pyrrolidino(propyloxy)phenyl H3R pharmacophore was introduced with overlap into an adenosine antagonist arylindenopyrimidine core. These MTLs showed distinct receptor binding profiles with overall nanomolar H3R affinities (Kii(A1R) = 11.5 nM,Ki(A2AR) = 7.25 nM) and 12( ST-1992,Ki(A1R) = 11.2 nM,Ki(A2AR) = 4.01 nM) were evaluatedin vivo.l-DOPA-induced dyskinesia was improved after administration of compound 4(1 mg kg-1, i.p. rats). Compound 12(2 mg kg-1, p.o. mice) increased wakefulness representing novel pharmacological tools for PD therapy.

FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS

Provided are certain fused tricyclic compounds and salts thereof, compositions thereof, and methods of use therefor.

Condensed tricyclic compounds as RAF kinase inhibitors

The invention provides certain condensed tricyclic compounds as well as salt, compositions and application methods thereof.

CONDENSED TRICYCLIC COMPOUNDS AS Raf KINASE INHIBITORS

PROBLEM TO BE SOLVED: To provide specific tricyclic compounds that can be useful for inhibiting Raf kinase and for treating disorders mediated by Raf kinase. SOLUTION: A compound is represented by the general formula 1 in the figure. (Q is C or N; W is C or N; X is CH2 or O; Y is NR12, O or S; Z is O, S, NR13, CO, SO, SO2 or CR13R14; R1 to R6 are each independently hydrogen, halogen, haloalkyl, alkyl or the like.) SELECTED DRAWING: None COPYRIGHT: (C)2017,JPO&INPIT

FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS

Provided are certain fused tricyclic compounds and salts thereof, compositions thereof, and methods of use therefor.

SUBSTITUTED HETEROCYCLIC DERIVATIVES AS GPR AGONISTS AND USES THEREOF

The present invention generally relates to substituted heterocyclic derivatives (the compounds of Formula (I)), processes for their preparation, pharmaceutical compositions containing said compounds, their use as G-protein coupled receptor (GPR) agonists, particularly as GPR40 agonists and methods of using these compounds in the treatment of GPR40 mediated diseases or conditions such as Type 2 diabetes, obesity, dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS

Provided are certain fused tricyclic compounds and salts thereof, compositions thereof, and methods of use therefor.

Discovery and optimization of potent GPR40 full agonists containing tricyclic spirocycles

GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique mechanism leading to little risk of hypoglycemia. We recently reported the discovery of AM-1638 (2), a potent full agonist of GPR40. In this repor

CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.